Lesson
Define the Constipation Phenotype
Constipation can mean hard stool, infrequent stool, straining, incomplete evacuation, obstruction sensation, or manual assistance. The dominant feature changes the differential and the treatment target.
- Stool form
- Frequency
- Straining
- Incomplete evacuation
- Manual maneuvers
Use Bristol form and effort, not frequency alone.
Outlet symptoms can persist even when stool is soft.
Track the result that reflects the patient's actual burden.
Start with the patient's definition
Fewer than three bowel movements per week is only one presentation. Hard stool, prolonged straining, incomplete evacuation, blockage sensation, and manual maneuvers can be more clinically important than frequency.
Separate CIC from IBS-C
Both conditions can include constipation, but recurrent abdominal pain linked to defecation or changed stool frequency or form is central to IBS. CIC centers on difficult or unsatisfactory defecation without the required IBS pain pattern.
Measure outcomes precisely
A spontaneous bowel movement occurs without rescue laxative use. A complete spontaneous bowel movement also includes a sense of complete evacuation. Frequency alone can improve while the patient's main burden remains unchanged.
Keep adjacent conditions separate
Medication-induced constipation, opioid-induced constipation, pediatric functional constipation, pregnancy-associated constipation, and structural or pelvic floor disorders require their own cause-specific decisions.
Quick check
Lesson
Triage Alarm Features and Secondary Causes
CIC is diagnosed after the pattern, timeline, examination, medication exposures, and targeted evaluation support a primary constipation disorder rather than an urgent or reversible cause.
- Alarm features
- Medication audit
- Metabolic causes
- Neurologic causes
- Structural disease
Alarm features move evaluation ahead of routine self-treatment.
Link symptom onset to opioids, anticholinergics, minerals, and other causes.
Order studies from history and examination rather than a universal panel.
Escalate alarm presentations
Gastrointestinal bleeding, iron-deficiency anemia, unintentional weight loss, fever, a mass, severe or progressive pain, persistent vomiting, acute obstipation, or an abrupt sustained change can justify urgent or broader evaluation.
Audit constipating medicines
Opioids, anticholinergics, iron, calcium, aluminum-containing antacids, some calcium channel blockers, clonidine, antipsychotics, tricyclic antidepressants, anticonvulsants, and other agents can create or amplify constipation. Do not add laxatives before asking whether the exposure can be reduced or replaced.
Test from clinical probability
Routine broad laboratory testing is not required for every patient. Thyroid, calcium, glucose, blood count, or other studies should follow the history, examination, risk factors, and alarm profile.
Exclude obstruction before acceleration
Severe distention, vomiting, inability to pass stool or gas, peritoneal findings, or known narrowing changes the pathway. Fiber, osmotic agents, stimulants, and secretagogues should not be used to push through suspected mechanical obstruction.
Quick check
Lesson
Recognize Defecatory Disorders
Soft stool can still be difficult to pass when rectal propulsion and pelvic floor relaxation are poorly coordinated. More laxation does not correct an outlet disorder.
- Digital rectal examination
- Balloon expulsion
- Anorectal manometry
- Biofeedback
- Defecography
Assess push, descent, and anal relaxation during a purposeful rectal examination.
Combine pressure physiology with practical evacuation performance.
Correct coordination instead of adding secretion to an unresolved outlet disorder.
Perform a purposeful examination
A digital rectal examination should assess resting tone, squeeze, perineal descent, rectal propulsion, and anal relaxation during simulated evacuation. A normal examination does not fully exclude dysfunction, but a cursory examination misses important physiology.
Use complementary anorectal tests
Anorectal manometry measures pressure and coordination while balloon expulsion tests practical evacuation. Findings must be interpreted together with symptoms and technique rather than as isolated numbers.
Treat the mechanism
Pelvic floor biofeedback retrains abdominal propulsion, anal relaxation, sensation, and toileting behavior. It is preferred over simply adding laxatives for a confirmed defecatory disorder.
Reserve imaging for unresolved anatomy or discordance
Defecography can clarify rectocele, intussusception, prolapse, excessive perineal descent, or conflicting anorectal results. It is not the first test for every patient with constipation.
Quick check
Lesson
Build a Measured Foundation
Foundational care should be specific, feasible, and measured. Generic advice to drink more water or exercise more is not a substitute for identifying the dominant mechanism.
- Psyllium
- Fluid
- Activity
- Toileting posture
- Titration
Psyllium creates a hydrated gel when titrated with safe fluid intake.
Create an unhurried post-meal opportunity with supportive posture.
A daily bowel movement is not the only definition of success.
Prefer soluble fiber
Psyllium is the best-supported fiber supplement in CIC. Begin with a small dose and titrate gradually because rapid escalation can cause gas, bloating, cramping, or impaction. Adequate fluid and safe swallowing are essential.
Use hydration precisely
Correct dehydration and support fiber with adequate fluid, but do not promise that forcing extra water cures constipation in a normally hydrated person. Heart failure, kidney disease, and swallowing limitations can constrain generic fluid advice.
Use the gastrocolic window
A regular unhurried toileting opportunity after a meal can use the gastrocolic response. A foot support can improve anorectal angle and reduce straining for some patients.
Set expectations
Success may mean several comfortable complete bowel movements per week with less straining and less rescue use. Daily stool is not required, and a treatment that increases frequency while worsening urgency may not be successful.
Quick check
Lesson
Use Osmotic Laxatives by Evidence and Physiology
Osmotic agents retain water in the intestinal lumen. Their evidence, electrolyte burden, fermentation, onset, and renal safety differ.
- Polyethylene glycol
- Magnesium oxide
- Lactulose
- Renal function
- Fermentation
Retains water with limited fermentation and a measurable stool response.
Accumulation risk changes selection when kidney function is reduced.
Gas and bloating can limit a therapy that increases luminal osmoles.
Use PEG as the evidence anchor
The 2023 joint guideline strongly recommends polyethylene glycol for adults with CIC. A common adult OTC dose is 17 g dissolved in 4 to 8 ounces of beverage once daily. Loose stool, bloating, cramping, or diarrhea can require adjustment.
Use magnesium selectively
Magnesium oxide is conditionally suggested. Avoid it in renal insufficiency because magnesium can accumulate. Separate magnesium from medicines whose absorption is reduced by polyvalent cations.
Use lactulose when it fits
Lactulose is conditionally suggested when other over-the-counter therapies are not adequate or appropriate. Colonic fermentation can produce gas, bloating, and cramping, which may limit adherence.
Do not confuse chronic guidance with package self-care limits
OTC labels for occasional constipation often direct short self-treatment and evaluation when symptoms persist. Long-term CIC management should occur within a clinician-guided plan with periodic reassessment.
Quick check
Lesson
Use Stimulants and Rescue Therapy Deliberately
Stimulant laxatives increase propulsive activity and secretion. They can provide rescue or scheduled therapy, but the plan should anticipate cramping, urgency, and overcorrection.
- Bisacodyl
- Sodium picosulfate
- Senna
- Rescue therapy
- Docusate evidence
Use short term or as rescue with coating-aware administration.
Titrate against cramping, urgency, and diarrhea.
Familiarity does not replace evidence of meaningful benefit.
Use the strong short-term recommendation
Bisacodyl and sodium picosulfate are strongly recommended for short-term treatment or rescue therapy. Bisacodyl oral delayed-release products should not be taken within one hour of milk, antacids, or acid-suppressing agents that can disrupt the coating.
Use senna with an individualized plan
Senna is conditionally suggested and can be titrated to effect. Abdominal cramping and diarrhea are common dose-limiting effects. Long-term use is not automatically forbidden, but benefit, dose, and adverse effects should be reviewed.
Avoid laxative myths
Appropriate stimulant use should not be described as inevitably addictive or destructive to the colon. The relevant questions are indication, dose, response, adverse effects, and whether an untreated evacuation disorder is present.
Do not elevate docusate beyond its evidence
The joint guideline did not provide a recommendation for docusate, and prior small trials have not established superiority to placebo. A familiar stool softener is not automatically the most effective treatment.
Quick check
Lesson
Select Intestinal Secretagogues
Lubiprostone, linaclotide, and plecanatide increase intestinal fluid through different epithelial targets. Dosing, meal timing, pediatric restrictions, and diarrhea plans are product-specific.
- Lubiprostone
- Linaclotide
- Plecanatide
- Chloride secretion
- Diarrhea safety
Use 24 mcg twice daily with food and water for adult CIC.
Use the CIC dose before a meal and stop for severe diarrhea.
Use 3 mg daily with flexible meal timing in adults.
Use lubiprostone for adult CIC
Lubiprostone is conditionally suggested and labeled at 24 mcg twice daily with food and water. Swallow capsules whole. Mechanical obstruction is a contraindication; nausea, diarrhea, syncope or hypotension, and transient dyspnea require counseling. Hepatic impairment can require a lower starting dose.
Use linaclotide at the CIC dose
Linaclotide is strongly recommended after over-the-counter failure. Adult CIC dosing is 145 mcg once daily, or 72 mcg based on presentation or tolerability, on an empty stomach at least 30 minutes before a meal. Do not substitute the 290 mcg adult IBS-C dose.
Use plecanatide with flexible meal timing
Plecanatide is strongly recommended after over-the-counter failure and labeled at 3 mg once daily with or without food in adults. It is contraindicated below age 6, should be avoided from age 6 through 17, and is contraindicated in mechanical obstruction.
Teach the shared stop rule
Severe diarrhea warrants interruption and rehydration. Each product needs an exact administration plan and a decision date rather than indefinite continuation without measured benefit.
Quick check
Lesson
Use Prucalopride as a Motility-Directed Option
Prucalopride is a selective serotonin 5-HT4 receptor agonist that stimulates enteric neurotransmission, peristaltic reflexes, secretion, and colonic motility.
- 5-HT4 agonism
- Renal adjustment
- Mood monitoring
- Obstruction
- Adverse effects
Selective 5-HT4 agonism strengthens the peristaltic reflex.
Use 2 mg daily, reduced to 1 mg in severe renal impairment.
Act on new depression, suicidal thinking, severe diarrhea, or persistent pain.
Use the labeled adult regimen
Prucalopride is strongly recommended after over-the-counter failure and labeled at 2 mg once daily with or without food. Use 1 mg once daily when creatinine clearance is below 30 mL/min.
Screen gastrointestinal contraindications
Do not use prucalopride in intestinal perforation or obstruction, obstructive ileus, or severe inflammatory conditions such as Crohn disease, ulcerative colitis, or toxic megacolon.
Monitor mood explicitly
The label warns about suicidal ideation and behavior and new or worsening depression. Discuss the signal before treatment and instruct patients and caregivers to stop the medicine and contact the prescriber if concerning changes emerge.
Prepare for early adverse effects
Headache, abdominal pain, nausea, and diarrhea are common. Some effects begin early and may resolve, but severe or persistent symptoms require reassessment.
Quick check
Lesson
Evaluate Refractory Constipation Before Escalating
Refractory constipation is not simply failure of one laxative. The diagnosis requires adequate trials, correction of secondary causes, pelvic floor evaluation when indicated, and objective characterization of transit.
- Adequate trials
- Anorectal testing
- Transit testing
- Defecography
- Combination therapy
Identify and treat a defecatory disorder before escalating the label.
Document slow transit and the persistence of disease on maximal treatment.
Require objective physiology and careful exclusion of poor-outcome patterns.
Confirm the groundwork
The 2026 AGA update advises evaluating most chronic constipation patients with anorectal manometry and balloon expulsion, with biofeedback when indicated, before applying a refractory label.
Measure colonic transit
Transit testing off treatment can document slow transit. Testing on a maximal regimen can help show that constipation remains refractory despite therapy. The result should be interpreted after outlet dysfunction and reversible causes are addressed.
Use defecography selectively
Defecography can clarify anatomy and evacuation when initial anorectal testing is inconclusive or discordant. It should answer a specific unresolved question.
Keep surgery last
Surgical therapy requires confirmed slow-transit constipation, exclusion of defecatory disorder, regional transit assessment, and careful review of psychological and clinical contraindications. Severe pain or bloating as the primary complaint predicts a less straightforward outcome.
Quick check
Lesson
Build a Safe Longitudinal Plan
Constipation care is a sequence of defined trials, not an accumulation of every laxative. Each step needs a target, stop rule, review date, and plan for changing physiology or life circumstances.
- Outcome tracking
- Combination therapy
- Deprescribing
- Pregnancy and lactation
- Patient counseling
Choose frequency, form, straining, completeness, pain, or function.
Use a planned review date instead of passive accumulation.
Alarm features or phenotype change require diagnostic reconsideration.
Use a treatment ladder without rigid delay
Begin with feasible foundational and over-the-counter therapy, then move to an evidence-supported prescription option when the trial is inadequate. Access, cost, adherence, and severity can alter the pace.
Combine by mechanism when necessary
Selected patients may need a prescription agent plus an over-the-counter agent or rescue stimulant. Combine intentionally, avoid supratherapeutic stacking, and simplify when benefit cannot be assigned to a component.
Reassess the diagnosis
New bleeding, anemia, weight loss, vomiting, severe pain, diarrhea, medication exposure, or a major bowel-pattern change reopens the differential. Do not keep escalating the old plan when the clinical story changes.
Use current reproductive safety information
Review pregnancy and lactation data for the exact product, including systemic exposure, human and animal data, milk transfer, disease burden, and alternatives. Do not use obsolete pregnancy-letter categories or assume that all laxatives share one risk profile.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 128 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- AGA and ACG guideline for pharmacologic management of chronic idiopathic constipation
- AGA clinical practice update for refractory constipation
- DailyMed polyethylene glycol 3350 drug facts
- DailyMed lubiprostone prescribing information
- DailyMed Linzess prescribing information
- DailyMed Trulance prescribing information
- DailyMed prucalopride prescribing information